{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T06:11:16Z","timestamp":1771827076661,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is a difficult-to-treat cancer with a 5-year survival rate of only 13%. Intense chemotherapies are needed to control the disease. Surgical resection, if possible, is the only curative approach. However, recurrence rates are high. The inclusion of immune checkpoint inhibitors in treatment hasn\u2019t shown benefit, most likely because of the cancer\u2019s highly immunosuppressive tumor microenvironment (TME). Leukemia Inhibitory Factor (LIF) is a cytokine that contributes to this profound immunosuppression, which is thought to be at least partly mediated by pro-tumoral (M2-like) tumor-associated macrophages (TAMs). Those macrophages harbor LIF receptors on their surface. The addition of the anti-LIF antibody MSC-1 to a combination of anti-programmed death-ligand 1 (anti-PD-L1) and chemotherapy has shown encouraging preclinical results, successfully reversing pro-tumoral TAMs into anti-tumoral (M1-like) macrophages. Here, we report a patient with recurrent PDAC in the abdominal wall and peritoneum, that immediately went into complete remission after receiving an investigational treatment with MSC-1 and anti-PD-L1 combined with standard-of-care chemotherapy. We discuss immunological mechanisms that may have contributed to the impressive treatment response.<\/jats:p>","DOI":"10.3389\/fonc.2026.1649850","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:28:21Z","timestamp":1771824501000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: An exceptional response to a novel immunotherapy-based combination treatment for resected pancreatic ductal adenocarcinoma with recurrence to the abdominal wall"],"prefix":"10.3389","volume":"16","author":[{"given":"Thomas","family":"Enzler","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Michigan","place":["Ann Arbor, MI, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Tweedy","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Michigan","place":["Ann Arbor, MI, United States"]},{"name":"Department of Pathology, University of Michigan","place":["Ann Arbor, MI, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Holmes","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan","place":["Ann Arbor, MI, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura W.","family":"Lamps","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan","place":["Ann Arbor, MI, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29100541","article-title":"The role of immunotherapy in pancreatic cancer","volume":"29","author":"Mukherji","year":"2022","journal-title":"Curr Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2206558","article-title":"Targeting leukemia inhibitory factor in pancreatic adenocarcinoma","volume":"32","author":"Wang","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6756","article-title":"Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction","volume":"7","author":"Yue","year":"2016","journal-title":"Oncotarget"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1130-6","article-title":"Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring","volume":"569","author":"Shi","year":"2019","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1158\/1078-0432.CCR-21-1888","article-title":"Therapeutic targeting of LIF overcomes macrophage-mediated immunosuppression of the local tumor microenvironment","volume":"29","author":"Hallett","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz073","article-title":"Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: A systematic review and patient-level meta-analysis","volume":"111","author":"Janssen","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B9","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.pan.2022.03.008","article-title":"Adjuvant therapy for margin positive pancreatic cancer: A propensity score matched analysis","volume":"22","author":"Takahashi","year":"2022","journal-title":"Pancreatology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.7728","article-title":"Evaluation of BRCA1 and BRCA2 as indicators of response to immune checkpoint inhibitors","volume":"4","author":"Zhou","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","article-title":"Therapeutic developments in pancreatic cancer","volume":"21","author":"Hu","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-051116-052215","article-title":"Antigen-presenting cells in the skin","volume":"35","author":"Kashem","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.830208","article-title":"Key players of the immunosuppressive tumor microenvironment and emerging therapeutic strategies","volume":"10","author":"Park","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00267","article-title":"The immune landscape of visceral adipose tissue during obesity and aging","volume":"11","author":"Khan","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: Advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155497","article-title":"Targeting of CD163(+) macrophages in inflammatory and Malignant diseases","volume":"21","author":"Skytthe","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052953","article-title":"A comparison of spatial and phenotypic immune profiles of pancreatic ductal adenocarcinoma and its precursor lesions","volume":"25","author":"Enzler","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41467-019-10369-9","article-title":"LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 therapy","volume":"10","author":"Pascual-Garcia","year":"2019","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.01.003","article-title":"Combining chemotherapy with PD-1 blockade in NSCLC","volume":"186","author":"Mathew","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00247-z","article-title":"Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer","volume":"2","author":"Westcott","year":"2021","journal-title":"Nat Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1007\/s00520-025-09952-2","article-title":"Hematologic immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"33","author":"Cruz Carreras","year":"2025","journal-title":"Support Care Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.2840","article-title":"First-line (1L) AZD0171 + durvalumab (D) + chemotherapy (CT) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): Phase II study results","volume":"36","author":"Chandana","year":"2025","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1649850\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:28:21Z","timestamp":1771824501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1649850\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":27,"alternative-id":["10.3389\/fonc.2026.1649850"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1649850","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"article-number":"1649850"}}